| Literature DB >> 30058101 |
Shufang Liu1, Chenghao Chu2, Alan Rong1.
Abstract
A cancer clinical trial with an immunotherapy often has 2 special features, which are patients being potentially cured from the cancer and the immunotherapy starting to take clinical effect after a certain delay time. Existing testing methods may be inadequate for immunotherapy clinical trials, because they do not appropriately take the 2 features into consideration at the same time, hence have low power to detect the true treatment effect. In this paper, we proposed a piece-wise proportional hazards cure rate model with a random delay time to fit data, and a new weighted log-rank test to detect the treatment effect of an immunotherapy over a chemotherapy control. We showed that the proposed weight was nearly optimal under mild conditions. Our simulation study showed a substantial gain of power in the proposed test over the existing tests and robustness of the test with misspecified weight. We also introduced a sample size calculation formula to design the immunotherapy clinical trials using the proposed weighted log-rank test.Entities:
Keywords: cure rate; immunotherapy; piece-wise proportional hazards cure rate model; random delayed treatment effect; sample size; weighted log-rank test
Mesh:
Year: 2018 PMID: 30058101 DOI: 10.1002/pst.1878
Source DB: PubMed Journal: Pharm Stat ISSN: 1539-1604 Impact factor: 1.894